CN110709091A - 使用长效格拉替雷和脂肪源性干细胞治疗多发性硬化症 - Google Patents

使用长效格拉替雷和脂肪源性干细胞治疗多发性硬化症 Download PDF

Info

Publication number
CN110709091A
CN110709091A CN201780091620.2A CN201780091620A CN110709091A CN 110709091 A CN110709091 A CN 110709091A CN 201780091620 A CN201780091620 A CN 201780091620A CN 110709091 A CN110709091 A CN 110709091A
Authority
CN
China
Prior art keywords
glatiramer acetate
hadscs
pharmaceutical composition
administration
administered
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201780091620.2A
Other languages
English (en)
Chinese (zh)
Inventor
埃胡德·马罗姆
纳达夫·布莱希·基梅尔曼
弗里达·格里恩斯潘
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Stem Cell Medicine Ltd
Mapi Pharma Ltd
Original Assignee
Stem Cell Medicine Ltd
Mapi Pharma Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Stem Cell Medicine Ltd, Mapi Pharma Ltd filed Critical Stem Cell Medicine Ltd
Publication of CN110709091A publication Critical patent/CN110709091A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/28—Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/02—Peptides of undefined number of amino acids; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0085—Brain, e.g. brain implants; Spinal cord

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Cell Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Developmental Biology & Embryology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • Biotechnology (AREA)
  • Virology (AREA)
  • Zoology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Psychology (AREA)
  • Dermatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Epoxy Compounds (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
CN201780091620.2A 2017-05-15 2017-05-15 使用长效格拉替雷和脂肪源性干细胞治疗多发性硬化症 Pending CN110709091A (zh)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/IL2017/050535 WO2018211486A1 (en) 2017-05-15 2017-05-15 Treatment of multiple sclerosis with long acting glatiramer and adipose-derived stem cells

Publications (1)

Publication Number Publication Date
CN110709091A true CN110709091A (zh) 2020-01-17

Family

ID=64273438

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201780091620.2A Pending CN110709091A (zh) 2017-05-15 2017-05-15 使用长效格拉替雷和脂肪源性干细胞治疗多发性硬化症

Country Status (8)

Country Link
US (1) US11413311B2 (cg-RX-API-DMAC7.html)
EP (1) EP3624815A4 (cg-RX-API-DMAC7.html)
JP (1) JP7000458B2 (cg-RX-API-DMAC7.html)
CN (1) CN110709091A (cg-RX-API-DMAC7.html)
AU (1) AU2017414803B2 (cg-RX-API-DMAC7.html)
CA (1) CA3062964C (cg-RX-API-DMAC7.html)
IL (1) IL270355B2 (cg-RX-API-DMAC7.html)
WO (1) WO2018211486A1 (cg-RX-API-DMAC7.html)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12097292B2 (en) 2016-08-28 2024-09-24 Mapi Pharma Ltd. Process for preparing microparticles containing glatiramer acetate
CN109982712A (zh) 2016-08-31 2019-07-05 Mapi医药公司 包含醋酸格拉替雷的储库系统
CN110382052A (zh) 2017-03-26 2019-10-25 Mapi医药公司 用于治疗进展型形式的多发性硬化症的格拉替雷储库系统

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090148419A1 (en) * 2005-12-07 2009-06-11 Cellerix, S.L. Use of adipose tissue derived mesenchymal stem cells for the treatment of graft versus host disease
US20090191173A1 (en) * 2004-11-29 2009-07-30 Michal Eisenbach-Schwartz Induction Of Neurogenesis And Stem Cell Therapy In Combination With Copolymer 1
US20120164229A1 (en) * 2010-01-04 2012-06-28 Mapi Pharma Ltd. Depot systems comprising glatiramer or pharmacologically acceptable salt thereof
CN102686235A (zh) * 2010-01-04 2012-09-19 Mapi医药公司 包含格拉默或其药用盐的储药系统
CN103403150A (zh) * 2010-12-17 2013-11-20 人类起源公司 利用羊膜来源贴壁细胞治疗与免疫相关的疾病和紊乱
CN104203901A (zh) * 2009-04-13 2014-12-10 C.T.瑞瑟露公司 治疗炎症的组合物和方法

Family Cites Families (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL36670A (en) 1971-04-21 1974-09-10 Sela M Therapeutic basic copolymers of amino acids
IL113812A (en) 1994-05-24 2000-06-29 Yeda Res & Dev Copolymer-1 pharmaceutical compositions containing it and its use
US6214791B1 (en) 1997-01-10 2001-04-10 Yeda Research And Development Co. Ltd. Treatment of multiple sclerosis through ingestion or inhalation of copolymer-1
JP4328050B2 (ja) 2000-01-20 2009-09-09 イエダ リサーチ アンド デベロップメント カンパニー リミテッド 神経保護療法のためのコポリマー１、関連ペプチド及びポリペプチドならびにそれらによって処理されたｔ細胞の使用
US8871241B2 (en) 2002-05-07 2014-10-28 Psivida Us, Inc. Injectable sustained release delivery devices
RU2339397C2 (ru) 2003-01-21 2008-11-27 Йеда Рисерч Энд Дивелопмент Ко.Лтд. Сор1 для лечения воспалительных заболеваний кишечника
US7429378B2 (en) 2003-05-13 2008-09-30 Depuy Spine, Inc. Transdiscal administration of high affinity anti-MMP inhibitors
US20060165667A1 (en) 2004-12-03 2006-07-27 Case Western Reserve University Novel methods, compositions and devices for inducing neovascularization
US20070003528A1 (en) 2005-06-29 2007-01-04 Paul Consigny Intracoronary device and method of use thereof
DK1957633T3 (en) 2005-10-13 2014-03-17 Anthrogenesis Corp Immunomodulation USING PLACE SPEECH STEM CELLS
WO2008024996A2 (en) 2006-08-24 2008-02-28 Johnstone Brian H Production of neural protective and regenerative factors from stem cells and treatment of nervous system conditions therewith
ES2663875T3 (es) 2006-11-03 2018-04-17 Multiple Sclerosis Research Center Of New York Células madre mesenquimáticas derivadas de la médula ósea como fuente de progenitores neurales
US8703180B1 (en) 2007-10-23 2014-04-22 Abbott Cardiovascular Systems Inc. Multiple growth factor compositions, methods of fabrication, and methods of treatment
WO2009115581A2 (en) 2008-03-19 2009-09-24 Cryo-Save Ag Improved cryopreservation of adipose tissue for the isolation of mesenchymal stem cells
US20090291061A1 (en) 2008-05-21 2009-11-26 Riordan Neil H Stem cell therapy for blood vessel degeneration
EP2620493B1 (en) 2008-05-28 2019-03-27 Ramot at Tel Aviv University Ltd. Mesenchymal stem cells for the treatment of CNS diseases
US20110129450A1 (en) 2008-08-01 2011-06-02 Orly Lazarov Method of promoting neurogenesis by modulating secretase activities
WO2010028051A2 (en) 2008-09-03 2010-03-11 Florida State University Research Foundation, Inc. Substituted heterocyclic mercaptosulfonamide metalloprotease inhibitors
CN102186968A (zh) 2008-10-17 2011-09-14 巴克斯特国际公司 从脂肪组织获得细胞群的方法
JP5515319B2 (ja) 2009-02-23 2014-06-11 富士レビオ株式会社 脂肪細胞への分化誘導培地及び方法
EP3150703A1 (en) 2009-07-09 2017-04-05 TiGenix, S.A.U. Cells for use in a method for treating inflammatory and/or immune disorders
US20120230966A1 (en) 2009-09-30 2012-09-13 Parcell Laboratories Llc Tissue transplant compositions and methods for use
CA2790436A1 (en) 2010-02-18 2011-08-25 Osiris Therapeutics, Inc. Immunocompatible chorionic membrane products
WO2012143924A1 (en) 2011-04-21 2012-10-26 Mapi Pharma Ltd. Random pentapolymer for treatment of autoimmune diseases
US20130034524A1 (en) 2011-08-03 2013-02-07 Siamak Agha-Mohammadi Non-Enzymatic Method for Harvesting Adipose-Derived Stromal Cells and Adipose-Derived Stem Cells from Fat and Lipo-Aspirate
EP2744892B1 (en) 2011-09-23 2019-03-20 Cell Ideas Pty Ltd. Therapeutics using adipose cells and cell secretions
CL2011002642A1 (es) 2011-10-24 2012-04-09 Univ Del Desarrollo Uso de una composicion formada por un glucocorticoide y una tiazolinediona que sirve para inducir la diferenciacion adipogenica en celulas madres.
EP2623110A1 (en) 2012-01-31 2013-08-07 CSL Behring GmbH Factor XII inhibitors for the treatment of neurological inflammatory disorders
SG11201405257WA (en) 2012-03-12 2014-09-26 Univ Singapore Generation of brown adipose tissue (bat) from mesenchymal cells
US20150216908A1 (en) 2014-02-06 2015-08-06 Steminent Biotherapeutics Inc. Quadri-positive stromal cell (qpsc) population for superior cell protection and immunomodulation
US20170065638A1 (en) 2014-02-10 2017-03-09 Cytori Therapeutics, Inc. Regenerative cell therapy for central nervous system (cns) disorders and ptsd
US20190046576A1 (en) 2016-02-12 2019-02-14 Cell Care Therapeutics Adipose tissue derived mesenchymal stromal cell conditioned media and methods of making and using the same
WO2018002930A1 (en) * 2016-06-30 2018-01-04 Stem Cell Medicine Ltd. Treatment of inflammatory bowel disease with long acting glatiramer and adipose-derived stem cells
EP3624816A4 (en) 2017-05-15 2021-02-24 Stem Cell Medicine Ltd. TREATMENT OF MULTIPLE SCLEROSIS WITH STEM CELLS DERIVED FROM ADIPOUS TISSUE

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090191173A1 (en) * 2004-11-29 2009-07-30 Michal Eisenbach-Schwartz Induction Of Neurogenesis And Stem Cell Therapy In Combination With Copolymer 1
US20090148419A1 (en) * 2005-12-07 2009-06-11 Cellerix, S.L. Use of adipose tissue derived mesenchymal stem cells for the treatment of graft versus host disease
CN104203901A (zh) * 2009-04-13 2014-12-10 C.T.瑞瑟露公司 治疗炎症的组合物和方法
US20120164229A1 (en) * 2010-01-04 2012-06-28 Mapi Pharma Ltd. Depot systems comprising glatiramer or pharmacologically acceptable salt thereof
CN102686235A (zh) * 2010-01-04 2012-09-19 Mapi医药公司 包含格拉默或其药用盐的储药系统
CN103403150A (zh) * 2010-12-17 2013-11-20 人类起源公司 利用羊膜来源贴壁细胞治疗与免疫相关的疾病和紊乱

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
BRITTNI A SCRUGGS等: "Age of the donor reduces the ability of human adipose-derived stem cells to alleviate symptoms in the experimental autoimmune encephalomyelitis mouse model", vol. 2, no. 2, pages 798 *
NAZEM GHASEMI等: "Transplantation of human adipose-derived stem cells enhances remyelination in lysolecithin-induced focal demyelination of rat spinal cord", vol. 56, no. 5 *

Also Published As

Publication number Publication date
US20200147141A1 (en) 2020-05-14
JP2020519658A (ja) 2020-07-02
IL270355B2 (en) 2023-06-01
IL270355B1 (cg-RX-API-DMAC7.html) 2023-02-01
WO2018211486A1 (en) 2018-11-22
AU2017414803B2 (en) 2025-02-13
IL270355A (cg-RX-API-DMAC7.html) 2019-12-31
AU2017414803A1 (en) 2019-12-05
JP7000458B2 (ja) 2022-02-10
CA3062964C (en) 2024-11-12
US11413311B2 (en) 2022-08-16
CA3062964A1 (en) 2018-11-22
EP3624815A4 (en) 2021-01-20
EP3624815A1 (en) 2020-03-25

Similar Documents

Publication Publication Date Title
US12161688B2 (en) Treatment of inflammatory bowel disease with long acting glatiramer and adipose-derived stem cells
JP5916622B2 (ja) グラチラマーまたはその薬理学的に許容される塩を含むデポーシステム
JP2024129012A (ja) 炎症の治療のための免疫修飾粒子
Gharagozloo et al. Therapeutic applications of nanomedicine in autoimmune diseases: from immunosuppression to tolerance induction
JP6837486B2 (ja) 加齢に関連する認知障害及び神経炎症を予防及び／又は治療する方法
US8377885B2 (en) Depot systems comprising glatiramer or pharmacologically acceptable salt thereof
EP3506921B1 (en) Depot systems comprising glatiramer acetate
EP3065765B1 (en) Use of il-22 dimers in manufacture of medicaments for treating pancreatitis
CA3050086A1 (en) Glatiramer depot systems for treating progressive forms of multiple sclerosis
IL270355B2 (en) Treatment of multiple sclerosis using long-acting glatiramer and stem cells derived from adipose tissue
JP7232752B2 (ja) 酢酸グラチラマーを含有する微小粒子を調製する方法
JP6573293B2 (ja) 炎症性疾患の予防または治療用ペプチド及びこの用途
USRE50301E1 (en) Depot systems comprising glatiramer or pharmacologically acceptable salt thereof
US20230399404A1 (en) Sustained antibody and immunotherapeutic delivery to cervical lymph nodes
KR20040079393A (ko) (-)-에피갈로카테킨 갈레이트를 유효성분으로 하는류마티스성 관절염 치료제
US20160022772A1 (en) Cytokine Receptors as Targets for Hypertension Therapy and Methods of Use
HK1173383A (en) Depot systems comprising glatiramer or a pharmacologically acceptable salt thereof

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
RJ01 Rejection of invention patent application after publication

Application publication date: 20200117

RJ01 Rejection of invention patent application after publication